Skip to main content
Premium Trial:

Request an Annual Quote

Almac to Partner with Lilly UK on Lung Cancer Dx

NEW YORK (GenomeWeb News) – Almac Diagnostics said today that it will collaborate with Lilly UK to develop a companion diagnostic for a combination lung cancer therapy.

The companies will evaluate a predictive marker for a drug combination used in treating non-squamous, non-small cell lung cancer patients. Specifically, they will study Thymidylate Synthase as a marker for response to the Eli Lilly drug pemetrexid (Alimta) in combination with cisplatin.

They also will study "alternative strategies" for developing other markers for the same combination therapy. The alternative studies will involve using global gene expression profiling from formalin-fixed paraffin-embedded tumor samples using Almac's Lung Cancer DSA microarray.

Almac said it will conduct global gene expression profiling, microRNA profiling, SNP genotyping, qPCR validation, and data analysis to develop the companion diagnostic.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.